Critical Limb Ischemia – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Critical Limb Ischemia – Pipeline Review, H1 2018’, provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia

– The report reviews pipeline therapeutics for Critical Limb Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Critical Limb Ischemia therapeutics and enlists all their major and minor projects

– The report assesses Critical Limb Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Critical Limb Ischemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AnGes MG Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Rexgenero Ltd

Symic Biomedical Inc

TaiGen Biotechnology Co Ltd

TikoMed AB

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Critical Limb Ischemia Overview

Critical Limb Ischemia Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Critical Limb Ischemia Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Critical Limb Ischemia Companies Involved in Therapeutics Development

AnGes MG Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Rexgenero Ltd

Symic Biomedical Inc

TaiGen Biotechnology Co Ltd

TikoMed AB

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Critical Limb Ischemia Drug Profiles

ACP-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AdipoCell Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alecmestencel-T Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASCT-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beperminogene perplasmid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate FGF2 for Critical Limb Ischemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

burixafor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-CLI Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Critical Limb Ischemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFx-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-104 NP Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Procell Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Refacell-CLI Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rejuveinix Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReN-009 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-030 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovacular Diseases and Asthma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-700 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-302 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Critical Limb Ischemia Dormant Projects

Critical Limb Ischemia Discontinued Products

Critical Limb Ischemia Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: EMA grants Rexgenero’s lead product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data

Jan 25, 2018: Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Jan 09, 2018: FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study

Dec 20, 2017: Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials

Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies

Oct 09, 2017: BioTech Identifies and Files Patent on ProCell Mechanism of Action in Saving Limbs from Amputation

Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells

Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology

Sep 26, 2017: Hemostemix Announces Agreement with CRO Service Provider Topstone Research

Sep 18, 2017: U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatment of Critical Limb Ischemia

Sep 07, 2017: Caladrius Biosciences to Participate at Upcoming September Conferences

Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Jul 10, 2017: Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017

Jan 23, 2017: Consortium including TrakCel awarded £1.4 million from Innovate UK for commercialisation of Rexgenero cell therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Critical Limb Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Critical Limb Ischemia Pipeline by AnGes MG Inc, H1 2018

Critical Limb Ischemia Pipeline by apceth Biopharma GmbH, H1 2018

Critical Limb Ischemia Pipeline by Athersys Inc, H1 2018

Critical Limb Ischemia Pipeline by BiogenCell Ltd, H1 2018

Critical Limb Ischemia Pipeline by Caladrius Biosciences Inc, H1 2018

Critical Limb Ischemia Pipeline by Cynata Therapeutics Ltd, H1 2018

Critical Limb Ischemia Pipeline by Hemostemix Inc, H1 2018

Critical Limb Ischemia Pipeline by Histocell SL, H1 2018

Critical Limb Ischemia Pipeline by ID Pharma Co Ltd, H1 2018

Critical Limb Ischemia Pipeline by Integene International Holdings LLC, H1 2018

Critical Limb Ischemia Pipeline by Juventas Therapeutics Inc, H1 2018

Critical Limb Ischemia Pipeline by Kang Stem Biotech Co Ltd, H1 2018

Critical Limb Ischemia Pipeline by Kasiak Research Pvt Ltd, H1 2018

Critical Limb Ischemia Pipeline by Neurofx Inc, H1 2018

Critical Limb Ischemia Pipeline by Nissan Chemical Industries Ltd, H1 2018

Critical Limb Ischemia Pipeline by Pharmicell Co Ltd, H1 2018

Critical Limb Ischemia Pipeline by Pluristem Therapeutics Inc, H1 2018

Critical Limb Ischemia Pipeline by ReNeuron Group Plc, H1 2018

Critical Limb Ischemia Pipeline by Rexgenero Ltd, H1 2018

Critical Limb Ischemia Pipeline by Symic Biomedical Inc, H1 2018

Critical Limb Ischemia Pipeline by TaiGen Biotechnology Co Ltd, H1 2018

Critical Limb Ischemia Pipeline by TikoMed AB, H1 2018

Critical Limb Ischemia Pipeline by U.S. Stem Cell Inc, H1 2018

Critical Limb Ischemia Pipeline by VESSL Therapeutics Ltd, H1 2018

Critical Limb Ischemia Pipeline by ViroMed Co Ltd, H1 2018

Critical Limb Ischemia Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2018

Critical Limb Ischemia Dormant Projects, H1 2018

Critical Limb Ischemia Dormant Projects, H1 2018 (Contd..1), H1 2018

Critical Limb Ischemia Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Critical Limb Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports